Keiko Sujino

Keiko Sujino has extensive work experience in the pharmaceutical and chemical industries. From 2023 onwards, they have held various roles in DICE Therapeutics, Inc., a subsidiary of Eli Lilly and Company, including Executive Director, Sr. Director, and Director in the DICE Process Chemistry department. Prior to that, they worked at Gilead Sciences from 2015 to 2022 as the Sr. Director of Chemical Development and Manufacturing. There, they oversaw outsourced manufacturing, supplier selection, and project execution for drug substances and raw materials. From 2006 to 2015, Keiko worked at Gilead Alberta ULC as a Sr. Research Scientist in Process Development. Keiko'sresponsibilities included strategizing drug substance process R&D, supervising laboratory scientists, and ensuring regulatory compliance. Before that, they worked at Degussa Raylo Chemicals as a Sr. Chemist in both chemical process R&D and manufacturing, specializing in oligonucleotide manufacturing. Keiko began their career at The Noguchi Institute, where they worked as a researcher, focusing on organic synthesis methodology development under the guidance of Dr. Teruaki Mukaiyama.

Keiko Sujino obtained a degree in BSc in Chemistry from Chiba University in 1989. Keiko then pursued a Master of Science (MS) degree in Organic Chemistry from Chiba University from 1989 to 1991. Keiko continued their education at Tokyo Institute of Technology, where they earned a Ph.D. in Organic Chemistry, completing their studies in 1995. Keiko later attended the University of Alberta from 1996 to 2000 as a Postdoctoral Researcher, specializing in Biocatalysis and Glycobiology. In 2022, Keiko obtained a RAPS Regulatory Affairs Certificate in Pharmaceuticals from the Regulatory Affairs Professionals Society (RAPS).